CO5280089A1 - IL-8 RECEIVER ANTAGONISTS - Google Patents

IL-8 RECEIVER ANTAGONISTS

Info

Publication number
CO5280089A1
CO5280089A1 CO01020681A CO01020681A CO5280089A1 CO 5280089 A1 CO5280089 A1 CO 5280089A1 CO 01020681 A CO01020681 A CO 01020681A CO 01020681 A CO01020681 A CO 01020681A CO 5280089 A1 CO5280089 A1 CO 5280089A1
Authority
CO
Colombia
Prior art keywords
alkyl
chloro
optionally substituted
aryl
heterocycle
Prior art date
Application number
CO01020681A
Other languages
Spanish (es)
Inventor
Qi
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5280089A1 publication Critical patent/CO5280089A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)

Abstract

Un compuesto de Fórmula (I):<EMI FILE="01020681_1" ID="1" IMF=JPEG >en la que:Rb es independientemente seleccionado del grupo que consiste en hidrógeno, NR6-R7, OH, ORa, alquilo C1-5, arilo, aril-alquilo C1-4, aril-alquenilo C2-4, cicloalquilo, cicloalquil-alquilo C1-5, heteroarilo, heteroaril-alquilo C1-4, heteroaril-alquenilo C2-4, heterociclo, hetero-ciclo-alquilo C1-4, y heterociclo-alquenilo C2-4, restos todos que pueden estar opcional e independientemente sustituidos de una a tres veces con un sustituyente seleccionado del grupo que consiste en halógeno, nitro, alquilo C1-4 halosustituido, alquilo C1-4, amino, amina mono- o di-sustituida con alquilo C1-4, ORa, C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxilo, NR9C(O)Ra, S(O)m´Ra, C(O)NR6R7, C(O)OH, C(O)ORa, S(O)2NR6R7, y NHS(O)2Ra; o los dos sustituyentes Rb están unidos para formar un anillo de 3-10 miembros opcionalmente sustituido y que contiene independientemente, además de carbono, de 1 a 3 restos seleccionados del grupo que consiste en NRa, O, S, SO y SO2, y en el que el sustituyente puede estar opcionalmente insaturado;Ra es seleccionado del grupo que consiste en los restos alquilo, arilo, aril-alquilo C1-4 heteroarilo, hetero-aril-alquilo C1-4, heterociclo, COOR13, y heterociclo-alquilo C1-4, todos los cuales pueden estar opcionalmente sustituidos;m es un número entero que tiene un valor de 1 a 3; m' es 0 o un número entero que tiene un valor de 1 o 2; n es un número entero que tiene un valor de 1 a 3; q es 0 o un número entero que tiene un valor de 1 a 10; t es 0 o un número entero que tiene un valor de 1 ó 2; s es un número entero que tiene un valor de 1 a 3; R1 es independientemente seleccionado del grupo que consiste en hidrógeno, halógeno, nitro, ciano, alquilo C1-10, alquilo C1-10 halosustituido, alquenilo C2-10, alcoxilo C1-10, alcoxilo C1-10 halosustituido, azida, S(O)tR4, (CR8R8)qS(O)tR4, hidroxilo, alquilo C1-4, - 2 -sustituido con hidroxilo, arilo, aril-alquilo C1-4, aril-alquenilo C2-10, ariloxilo, aril-alquiloxilo C1-4, heteroarilo, heteroarilalquilo, heteroaril-alquenilo C2-10, hetero-aril-alquiloxilo C1-4, heterociclo, heterociclo-alquilo C1-4, heterociclo-alquiloxilo C1-4, heterociclo-alquenilo C2-10, (CR8R8)qNR4R5, (CR8R8)qC(O)NR4R5, alquenil C2-10- C(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alquenil C2-10-C(O)R11, alquenil C2-10-C(O)OR11, (CR8R8)q-C(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)q-C(NR4)NR4R5, (CR8R8)qNR4C(NR5)R11, (CR8R8)qNHS(O)2R13, y (CR8R8)q- S(O)2NR4R5; o dos restos R1 pueden formar conjuntamente O-(CH2)SO o un anillo saturado o insaturado de 5 a 6 miembros, pudiendo estar opcionalmente sustituidos los restos alquilo, arilo, arilalquilo, heteroarilo y heterociclo;R4 y R5 son independientemente seleccionados del grupo que consiste en hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo C1-4 opcionalmente sustituido, heterociclo y heterociclo alquilo C1-4; o R4 y R5 junto con el nitrógeno al que están unidos forman un anillo de 5 a 7 miembros que puede comprender opcionalmente un heteroátomo adicional seleccionado entre O, N y S; R6 y R7 son independientemente seleccionados del grupo que consiste en hidrógeno, alquilo C1-4, heteroarilo, arilo, alquilarilo, y alquil-heteroalquilo C1-4; o R6 y R7 junto con el nitrógeno al que están unidos forman un anillo de 5 a 7 miembros, anillo que puede contener opcionalmente un heteroátomo adicional seleccionado entre oxígeno, nitrógeno y azufre y que puede estar opcionalmente sustituido;Y es seleccionado del grupo que consiste en CR14R15, NR14, O, CO, y S(O)t;R8 es hidrógeno o alquilo C1-4;R9 es alquilo C1-4;R10 es alquil C1-10-C(O)2R8;R11 es seleccionado del grupo que consiste en hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo C1-4 opcionalmente sustituido, heterociclo opcionalmente sustituido, y heterociclo-alquilo C1-4 opcionalmente sustituido;R12 es seleccionado del grupo que consiste en hidrógeno, alquilo C1-4, arilo, aril-alquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclo y heterociclo-alquilo C1-4;R13 es seleccionado del grupo que consiste en alquilo C1-4, arilo, aril-alquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclo, y heterociclo-alquilo C1-4; yR14 y R15 son independientemente seleccionados del grupo que consiste en hidrógeno, alquilo C1-4 opcionalmente sustituido, ORa, y NR4R5; o R14 y R15 junto con el(los) átomo(s) al(a los) que están unidos pueden formar un anillo de 4 a 7 miembros que puede contener opcionalmente un heteroátomo adicional que es seleccionado del grupo que consiste en oxigeno, nitrógeno y azufre, anillo que puede estar opcionalmente sustituido;o una sal farmacéuticamente aceptable del mismo. Un compuesto de acuerdo con la Reivindicación 1, que es seleccionado del grupo que consiste en: N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N' -ciclohexilurea;N-(3-aminosulfonil-4-cloro-2-hidroxifenil)-N' - (1-adamantu) urea;N- (3-aminosulfonil-4-cloro-2-hidroxifenil) -N' - (tetrahidro-2-piranil) urea;N-(4-cloro-2-hidroxi-3-sulfamilfenil),-N´- (3-tetrahidrofuril) urea;6-cloro-2-hidroxi-3-[3-(2-metil-ciclopropil)-ureido]- -bencenosulfonamida;N-(4-cloro-2-hidroxi-3-sulfamilfenil)-N' -ciclohexilurea;6-cloro-2-hidroxi-3-[3-(2,2,3,3-tetrametil-ciclopropil)-ureido]-bencenosulfonamida;6-cloro-2-hidroxi-3-(3-piperidin-4-il-ureido) -benceno-sulfonamida;N-(4-cloro-2-hidroxi-3-sulfamilfenil)-N´-(4-metil-ciclohexil) urea;6-cloro-2-hidroxi-3-[3-(3-metoxi-ciclohexil)ureido]-bencenosulfonamida;N- (4-cloro-2 -hidroxi -3-sulfamilfenil) -N´-ciclopentilurea;N- (4-cloro-2-hidroxi-3-sulfamilfenil) -N' -ciclobutilurea;N-(4-cloro-2-hidroxi-3-sulfamilfenil) -N' -ciclopropilurea;éster terc-butílico del ácido 4-[6-cloro-3-(3-ciclopentil-ureido)-2-hidroxi-bencenosulfonil] -piperazina-1 -carboxílico;1- (4-cloro-2-hidroxi-3- (piperazina-1-sulfonil)-fenil] -3-ciclopentil -urea;éster terc-butílico del ácido 4-(6-cloro-3-(3-ciclobutil-ureido)-2-hidroxi-bencenosulfonil] -piperazina-1-carboxílico;3-{3-[(1S,2S)-2-benciloxi-ciclohexil]-ureido}-6-cloro-2-hidroxi- bencenosulfonamida; y6-cloro-3-(3-ciclobutil-ureido)-2-hidroxi-N,N'-dimetil--bencenosulfonamida.A compound of Formula (I): <EMI FILE = "01020681_1" ID = "1" MFI = JPEG> in which: Rb is independently selected from the group consisting of hydrogen, NR6-R7, OH, ORa, C1- alkyl 5, aryl, arylC 1-4 alkyl, arylC2-4 alkenyl, cycloalkyl, cycloalkylC1-5 alkyl, heteroaryl, heteroarylC1-4 alkyl, heteroarylC2-4 alkenyl, heterocycle, heterocycloalkyl C1-4, and C2-4 heterocyclo-alkenyl, moieties which may be optionally and independently substituted one to three times with a substituent selected from the group consisting of halogen, nitro, halosubstituted C1-4 alkyl, C1-4 alkyl, amino, mono- or di-substituted amine with C1-4 alkyl, ORa, C (O) Ra, NRaC (O) ORa, OC (O) NR6R7, hydroxyl, NR9C (O) Ra, S (O) m'Ra , C (O) NR6R7, C (O) OH, C (O) ORa, S (O) 2NR6R7, and NHS (O) 2Ra; or the two Rb substituents are joined to form an optionally substituted 3-10 membered ring and independently containing, in addition to carbon, 1 to 3 moieties selected from the group consisting of NRa, O, S, SO and SO2, and in which the substituent may be optionally unsaturated; Ra is selected from the group consisting of the alkyl, aryl, aryl-C1-4 alkyl heteroaryl, hetero-aryl-C1-4 alkyl, heterocycle, COOR13, and heterocycle-C1- alkyl moieties 4, all of which may be optionally substituted: m is an integer having a value of 1 to 3; m 'is 0 or an integer that has a value of 1 or 2; n is an integer that has a value of 1 to 3; q is 0 or an integer that has a value from 1 to 10; t is 0 or an integer that has a value of 1 or 2; s is an integer that has a value of 1 to 3; R1 is independently selected from the group consisting of hydrogen, halogen, nitro, cyano, C1-10 alkyl, halosubstituted C1-10 alkyl, C2-10 alkenyl, C1-10 alkoxy, halosubstituted C1-10 alkoxy, azide, S (O) tR4, (CR8R8) qS (O) tR4, hydroxyl, C1-4 alkyl, -2-substituted with hydroxyl, aryl, arylC 1-4 alkyl, arylC2-10 alkenyl, aryloxy, arylC 1-4 alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl-C2-10 alkenyl, hetero-aryl-C1-4 alkyloxy, heterocycle, heterocycle-C1-4 alkyl, heterocycle-C1-4 alkyloxy, heterocyclo-C2-10 alkenyl, (CR8R8) qNR4R5, (CR8R8 ) qC (O) NR4R5, C2-10-C alkenyl (O) NR4R5, (CR8R8) qC (O) NR4R10, S (O) 3R8, (CR8R8) qC (O) R11, C2-10-C alkenyl (O ) R11, alkenyl C2-10-C (O) OR11, (CR8R8) qC (O) OR11, (CR8R8) qOC (O) R11, (CR8R8) qNR4C (O) R11, (CR8R8) qC (NR4) NR4R5, (CR8R8) qNR4C (NR5) R11, (CR8R8) qNHS (O) 2R13, and (CR8R8) q- S (O) 2NR4R5; or two R1 moieties can together form O- (CH2) SO or a saturated or unsaturated ring of 5 to 6 members, the alkyl, aryl, arylalkyl, heteroaryl and heterocycle moieties being optionally substituted; R4 and R5 are independently selected from the group that it consists of hydrogen, optionally substituted C1-4 alkyl, optionally substituted aryl, optionally substituted aryl-C1-4 alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-C1-4 alkyl, heterocycle and C1-4 alkyl heterocycle; or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O, N and S; R6 and R7 are independently selected from the group consisting of hydrogen, C1-4 alkyl, heteroaryl, aryl, alkylaryl, and C1-4 alkyl heteroalkyl; or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7-membered ring, which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen and sulfur and which may be optionally substituted; and is selected from the group consisting in CR14R15, NR14, O, CO, and S (O) t; R8 is hydrogen or C1-4 alkyl; R9 is C1-4 alkyl; R10 is C1-10-C alkyl (O) 2R8; R11 is selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, optionally substituted aryl, optionally substituted aryl-C1-4 alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-C1-4 alkyl, optionally substituted heterocycle, and optionally substituted heterocycle-C1-4 alkyl substituted; R12 is selected from the group consisting of hydrogen, C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl, heteroaryl-C1-4 alkyl, heterocycle and heterocycle-C1-4 alkyl; R13 is selected from the group that consists of C1-4 alkyl, aryl, aryl- C1-4 alkyl, heteroaryl, heteroaryl-C1-4 alkyl, heterocycle, and heterocycle-C1-4 alkyl; and R14 and R15 are independently selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, ORa, and NR4R5; or R14 and R15 together with the atom (s) to which they are attached can form a 4- to 7-membered ring that may optionally contain an additional heteroatom that is selected from the group consisting of oxygen, nitrogen and sulfur, a ring that may be optionally substituted; or a pharmaceutically acceptable salt thereof. A compound according to Claim 1, which is selected from the group consisting of: N- (3-aminosulfonyl-4-chloro-2-hydroxyphenyl) -N '-cyclohexylurea; N- (3-aminosulfonyl-4-chloro- 2-hydroxyphenyl) -N '- (1-adamantu) urea; N- (3-aminosulfonyl-4-chloro-2-hydroxyphenyl) -N' - (tetrahydro-2-pyranyl) urea; N- (4-chloro- 2-hydroxy-3-sulfamilphenyl), - N '- (3-tetrahydrofuryl) urea; 6-chloro-2-hydroxy-3- [3- (2-methyl-cyclopropyl) -ureido] - -benzenesulfonamide; N- ( 4-Chloro-2-hydroxy-3-sulfamilphenyl) -N '-cyclohexylurea; 6-chloro-2-hydroxy-3- [3- (2,2,3,3-tetramethyl-cyclopropyl) -ureido] -benzenesulfonamide; 6-Chloro-2-hydroxy-3- (3-piperidin-4-yl-ureido) -benzene-sulfonamide; N- (4-Chloro-2-hydroxy-3-sulfamphenyl) -N´- (4-methyl- cyclohexyl) urea; 6-chloro-2-hydroxy-3- [3- (3-methoxy-cyclohexyl) ureido] -benzenesulfonamide; N- (4-chloro-2-hydroxy-3-sulfamphenyl) -N'-cyclopentylurea; N- (4-Chloro-2-hydroxy-3-sulfamilphenyl) -N '-cyclobutylurea; N- (4-chloro-2-hydroxy-3-sulfamilphenyl) -N'-cyclopropylurea; tert-butyl ester of á 4- [6-Chloro-3- (3-cyclopentyl-ureido) -2-hydroxy-benzenesulfonyl] -piperazine-1-carboxylic acid; 1- (4-chloro-2-hydroxy-3- (piperazine-1-sulfonyl) ) -phenyl] -3-cyclopentyl-urea; 4- (6-chloro-3- (3-cyclobutyl-ureido) -2-hydroxy-benzenesulfonyl] -piperazine-1-carboxylic acid tert-butyl ester; 3- { 3 - [(1S, 2S) -2-benzyloxy-cyclohexyl] -ureido} -6-chloro-2-hydroxybenzenesulfonamide; and 6-chloro-3- (3-cyclobutyl-ureido) -2-hydroxy-N, N'-dimethyl-benzenesulfonamide.

CO01020681A 2000-03-16 2001-03-14 IL-8 RECEIVER ANTAGONISTS CO5280089A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18984800P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
CO5280089A1 true CO5280089A1 (en) 2003-05-30

Family

ID=22699008

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01020681A CO5280089A1 (en) 2000-03-16 2001-03-14 IL-8 RECEIVER ANTAGONISTS

Country Status (23)

Country Link
EP (1) EP1263427A4 (en)
JP (1) JP2003526664A (en)
KR (1) KR20020091130A (en)
CN (1) CN1424910A (en)
AP (1) AP2002002606A0 (en)
AR (1) AR031098A1 (en)
AU (1) AU2001250873A1 (en)
BG (1) BG107013A (en)
BR (1) BR0108749A (en)
CA (1) CA2403062A1 (en)
CO (1) CO5280089A1 (en)
CZ (1) CZ20023075A3 (en)
DZ (1) DZ3317A1 (en)
EA (1) EA200200981A1 (en)
HU (1) HUP0300470A3 (en)
MA (1) MA25659A1 (en)
MX (1) MXPA02009094A (en)
NO (1) NO20024367L (en)
OA (1) OA12231A (en)
PL (1) PL366034A1 (en)
SK (1) SK13282002A3 (en)
WO (1) WO2001068084A1 (en)
ZA (1) ZA200207325B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030689A1 (en) * 2000-03-14 2003-09-03 Smithkline Beecham Corp 3-AMINOSULFONIL-2-HYDROXIFENYL UREA COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND USE OF SUCH COMPOUNDS IN THE MANUFACTURE OF MEDICINES TO TREAT CHEMIOQUINE MEDIUM DISEASES
CA2565519A1 (en) 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
BRPI0710232B8 (en) * 2006-04-21 2021-05-25 Glaxosmithkline Llc IL-8 receptor antagonist compound, pharmaceutical composition comprising said compound and use thereof for the treatment of a chemokine-mediated disease
CN101495113A (en) * 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 IL-8 receptor antagonists
CR20160557A (en) * 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd COMPOUNDS DERIVED FROM 1- (CICLOPENT-2-EN-1-IL) -3- (2-HIDROXI-3- (ARILSULFONIL) PHENYL) UREA AS CXCR2 INHIBITORS
BR112017002060A2 (en) * 2014-07-31 2017-12-26 Glaxosmithkline Ip Dev Ltd new use
CN111727184B (en) * 2018-01-11 2022-06-28 深圳嘉科生物科技有限公司 CXCR2 antagonists
EP3998256A4 (en) * 2019-07-11 2023-07-19 Shenzhen Optimum Biological Technology Co., Ltd Crystalline form of cxcr2 antagonist and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
AU3409197A (en) * 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2001501918A (en) * 1996-08-21 2001-02-13 スミスクライン・ビーチャム・コーポレイション IL-8 receptor antagonist
PL198394B1 (en) * 1998-09-23 2008-06-30 Amgen Inc Arylsulfonanilide ureas
UY25842A1 (en) * 1998-12-16 2001-04-30 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
CZ20023075A3 (en) 2003-05-14
BR0108749A (en) 2004-06-29
PL366034A1 (en) 2005-01-24
WO2001068084A1 (en) 2001-09-20
OA12231A (en) 2003-11-07
NO20024367L (en) 2002-10-22
ZA200207325B (en) 2003-10-17
KR20020091130A (en) 2002-12-05
EP1263427A4 (en) 2005-08-24
AU2001250873A1 (en) 2001-09-24
SK13282002A3 (en) 2003-02-04
JP2003526664A (en) 2003-09-09
HUP0300470A3 (en) 2005-05-30
CA2403062A1 (en) 2001-09-20
NO20024367D0 (en) 2002-09-12
CN1424910A (en) 2003-06-18
AP2002002606A0 (en) 2002-09-30
MXPA02009094A (en) 2003-03-12
EP1263427A1 (en) 2002-12-11
AR031098A1 (en) 2003-09-10
EA200200981A1 (en) 2003-02-27
DZ3317A1 (en) 2001-09-20
HUP0300470A2 (en) 2003-06-28
BG107013A (en) 2003-05-30
MA25659A1 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
CO5280089A1 (en) IL-8 RECEIVER ANTAGONISTS
AR032398A1 (en) SULFONAMIDE ESCUARAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND TO PREPARE SUCH COMPOSITION
PE20070195A1 (en) HISTONE DEACETILASE INHIBITORS
EA200201259A1 (en) DERIVATIVES OF BENZIMIDAZOLE, THEIR RECEPTION AND THERAPEUTIC APPLICATION
CO4990929A1 (en) DIFENILUREA COMPOUNDS SUBSTITUTED WITH SULFONAMIDES AS ANTAGONISTS OF IL-8 RECEPTORS
AR046605A1 (en) HYDROXAMATES UNITED TO BIARILO; PREPARATION AND PHARMACEUTICAL APPLICATIONS
TR200401413T1 (en) Dibenzylamine compounds and their pharmaceutical uses
CO5261605A1 (en) PHARMACEUTICAL COMPOUNDS
WO2004017908A3 (en) Calcium receptor modulating compound and use thereof
CO5261626A1 (en) REPLACED GLUTARIMIDES, ITS PREPARATION, DRUGS THAT CONTAIN THEM, AND USE OF THE SAME FOR THE MANUFACTURE OF DRUGS, ESPECIALLY IMMUNOMODULATORS, AS WELL ALSO INHIBITORS OF ANGIOPATIAS AND / OR HEMATOLOGICAL DISEASES / ONCOLOGICAL DISEASES
KR920002562A (en) Guanidine
LU88769I2 (en) Bicalutamide and its pharmaceutically acceptable salts and esters (Casodex (R))
NO20072690L (en) Benzene compounds with 2 or more substituents
PE20010987A1 (en) NON-PEPTIDIC INHIBITORS OF THE VLA-4 DEPENDENT CELL UNION USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES
DK0559046T3 (en) N-amidopiperidinyl (3/4) or N-amidino-1,4-oxazinyl (2) -substituted sulfonamides, method of preparation and use as thrombin inhibitors
NO333251B1 (en) Process for the preparation of N-substituted 2-cyanopyrrolidones
BR9307595A (en) Compound, process for its preparation, herbicidal composition, and process for severely damaging or exterminating undesirable plants
RU2001126579A (en) Organic compounds
DK1585493T3 (en) Triazine derivatives as UV absorbents
CO5080729A1 (en) BENZIMIDAZOLES, ITS PREPARATION AND DRUGS THAT CONTAIN THEM
CO5601012A2 (en) COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR
HRP20080022T3 (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
DE69710204T2 (en) ALPHA-AMINO SULFONYL HYDROXAMIC ACID AS A MATRIX METALLOPROTEINASE INHIBITOR
ES2369837T3 (en) TRIHETEROCYCLIC COMPOUNDS AS RECRUITOR ANTIGONISTS CFR.
TR199800628T2 (en) 8-Azabisiklo $ 3.2.1] oct-2-en t�revleri, büllar�n haz�rlanmas� ve kullan�m�.

Legal Events

Date Code Title Description
FA Application withdrawn